• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

社会人口学共变量对新诊断慢性髓系白血病患者预后、酪氨酸激酶抑制剂使用和结局的影响。

Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia.

机构信息

National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing, 100044, China.

Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, UK.

出版信息

J Cancer Res Clin Oncol. 2022 Feb;148(2):449-459. doi: 10.1007/s00432-021-03624-4. Epub 2021 Apr 9.

DOI:10.1007/s00432-021-03624-4
PMID:33835260
Abstract

PURPOSE

Define the impact of socio-demographic co-variates on outcomes of persons with newly-diagnosed chronic phase chronic myeloid leukaemia (CML).

METHODS

Data of 961 consecutive subjects with newly-diagnosed CML were integrated for these outcomes in multi-variable Cox regression analyses after adjusting for confounders and interactions.

RESULTS

Elder age was associated with less use of a 2nd generation TKI as initial therapy. Household registration, comorbidity(ies) and education level were associated with use of a generic rather than branded TKI as initial therapy. Subjects with lower education level were more likely to be diagnosed with CML because of leukaemia-related symptoms. Rural registration and lower education level were also associated with a greater likelihood of switching TKI-therapy. Lower education level was associated with lower likelihood of achieving MMR [HR = 0.8 (0.7, 0.9), p = 0.002], MR [HR = 0.8 (0.7, 1.0), p = 0.055], and poor FFS [HR = 1.7 (1.3, 2.5); p < 0.001], PFS [HR = 2.0 (1.1, 5.0); p = 0.014], CML-related survival [HR = 2.5 (1.0, 10.0); p = 0.060] and survival [HR = 2.5 (1.0, 10.0); p = 0.043]. Males had lower rates of MMR and MR and worse FFS, but not survival compared with females. Being married was associated with a higher rate of MR, fewer failures, progressions, and deaths.

CONCLUSION

Socio-demographic co-variates have a strong impact on therapy choice and responses in persons with newly-diagnosed CML, including circumstances of diagnosis, risk category and prognosis, use of initial TKI, switching TKIs, response to TKI-therapy, and outcomes.

摘要

目的

定义社会人口统计学协变量对新诊断的慢性期慢性髓系白血病(CML)患者结局的影响。

方法

对 961 例新诊断为 CML 的连续患者的数据进行整合,在多变量 Cox 回归分析中调整混杂因素和相互作用后,评估这些结局。

结果

年龄较大与作为初始治疗的第二代 TKI 的使用率较低有关。户籍、合并症和教育水平与初始治疗使用仿制药而非品牌 TKI 有关。教育水平较低的患者因白血病相关症状而更有可能被诊断为 CML。农村户籍和较低的教育水平也与更有可能转换 TKI 治疗有关。较低的教育水平与较低的 MMR 缓解率[HR=0.8(0.7,0.9),p=0.002]、MR 缓解率[HR=0.8(0.7,1.0),p=0.055]、较差的无失败生存[HR=1.7(1.3,2.5);p<0.001]、PFS 无进展生存[HR=2.0(1.1,5.0);p=0.014]、CML 相关生存[HR=2.5(1.0,10.0);p=0.060]和生存[HR=2.5(1.0,10.0);p=0.043]有关。与女性相比,男性的 MMR 和 MR 缓解率较低,无失败生存率较差,但生存情况无差异。已婚与较高的 MR 缓解率、较少的失败、进展和死亡有关。

结论

社会人口统计学协变量对新诊断的 CML 患者的治疗选择和反应有很大影响,包括诊断情况、风险类别和预后、初始 TKI 的使用、TKI 的转换、TKI 治疗的反应和结局。

相似文献

1
Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia.社会人口学共变量对新诊断慢性髓系白血病患者预后、酪氨酸激酶抑制剂使用和结局的影响。
J Cancer Res Clin Oncol. 2022 Feb;148(2):449-459. doi: 10.1007/s00432-021-03624-4. Epub 2021 Apr 9.
2
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者中与患者报告结局相关的变量。
J Cancer Res Clin Oncol. 2017 Jun;143(6):1013-1022. doi: 10.1007/s00432-017-2353-2. Epub 2017 Mar 1.
3
Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China.中国慢性髓性白血病酪氨酸激酶抑制剂治疗的分子监测
J Cancer Res Clin Oncol. 2016 Jul;142(7):1549-55. doi: 10.1007/s00432-016-2158-8. Epub 2016 Apr 16.
4
Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.酪氨酸激酶抑制剂治疗的自付费用较高与慢性髓性白血病患者健康相关生活质量较差有关。
J Cancer Res Clin Oncol. 2017 Dec;143(12):2619-2630. doi: 10.1007/s00432-017-2517-0. Epub 2017 Sep 11.
5
Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.患者及血液科医生对慢性髓性白血病酪氨酸激酶抑制剂治疗的担忧。
J Cancer Res Clin Oncol. 2018 Apr;144(4):735-741. doi: 10.1007/s00432-018-2594-8. Epub 2018 Jan 29.
6
Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.在中国慢性髓性白血病患者中,年轻和高成本与未来停止酪氨酸激酶抑制剂治疗的偏好相关。
J Cancer Res Clin Oncol. 2016 Jul;142(7):1539-47. doi: 10.1007/s00432-016-2159-7. Epub 2016 Apr 16.
7
[Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].[社会人口统计学和临床协变量相结合预测慢性期慢性髓性白血病患者的治疗反应和结局]
Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):54-62. doi: 10.3760/cma.j.issn.0253-2727.2022.01.011.
8
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.真实世界中慢性髓系白血病根据基线风险和一线治疗的结局:来自意大利网络/CML校园的数据。
Cancer. 2025 Jul 1;131(13):e35963. doi: 10.1002/cncr.35963.
9
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.新型酪氨酸激酶抑制剂与伊马替尼在不同风险组慢性期慢性髓性白血病一线治疗中的疗效比较:八项随机试验的系统评价和荟萃分析
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e85-94. doi: 10.1016/j.clml.2016.03.003. Epub 2016 Mar 30.
10
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.达沙替尼、尼洛替尼和标准剂量伊马替尼一线治疗慢性髓性白血病:系统评价和经济分析。
Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420.

引用本文的文献

1
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.慢性髓性白血病患者接受酪氨酸激酶抑制剂治疗后治疗失败的预测模型。
Blood. 2024 Oct 31;144(18):1951-1961. doi: 10.1182/blood.2024024761.
2
[Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].酪氨酸激酶抑制剂治疗初诊慢性髓性白血病的现状:一项国内多中心回顾性真实世界研究
Zhonghua Xue Ye Xue Za Zhi. 2024 Mar 14;45(3):215-224. doi: 10.3760/cma.j.cn121090-20231108-00255.
3
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors.

本文引用的文献

1
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
2
Racial/ethnic, age and sex disparities in leukemia survival among adults in the United States during 1973-2014 period.1973-2014 年期间美国成年人白血病存活率的种族/民族、年龄和性别差异。
PLoS One. 2019 Aug 19;14(8):e0220864. doi: 10.1371/journal.pone.0220864. eCollection 2019.
3
Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database.
酪氨酸激酶抑制剂治疗慢性髓性白血病期间患者与医生的管理视角
Oncol Ther. 2024 Mar;12(1):131-145. doi: 10.1007/s40487-023-00255-2. Epub 2023 Dec 16.
4
[Survey and analysis of the concerns of patients with chronic myeloid leukemia in China in 2021].[2021年中国慢性髓系白血病患者关注问题的调查与分析]
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):760-765. doi: 10.3760/cma.j.issn.0253-2727.2022.09.008.
5
[Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].[社会人口统计学和临床协变量相结合预测慢性期慢性髓性白血病患者的治疗反应和结局]
Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):54-62. doi: 10.3760/cma.j.issn.0253-2727.2022.01.011.
在一个公平获得医疗保健的体系中,社会经济地位、种族与根治性前列腺切除术的长期预后:来自 SEARCH 数据库的结果。
Urol Oncol. 2019 Apr;37(4):289.e11-289.e17. doi: 10.1016/j.urolonc.2018.12.004. Epub 2018 Dec 28.
4
Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.在 12 个月时达到最佳反应与慢性髓性白血病患者更好的健康相关生活质量相关:一项前瞻性、纵向、单中心研究。
BMC Cancer. 2018 Aug 3;18(1):782. doi: 10.1186/s12885-018-4699-5.
5
Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.台湾慢性粒细胞白血病患者使用酪氨酸激酶抑制剂的副作用及药物依从性
Medicine (Baltimore). 2018 Jun;97(26):e11322. doi: 10.1097/MD.0000000000011322.
6
Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: A population-based cohort study.社会经济地位对食管癌诊断分期、治疗接受情况及生存的影响:一项基于人群的队列研究。
PLoS One. 2017 Oct 11;12(10):e0186350. doi: 10.1371/journal.pone.0186350. eCollection 2017.
7
Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.慢性髓性白血病诊断时的保险状态与总生存期之间的关联:一项基于人群的研究。
Cancer. 2017 Jul 1;123(13):2561-2569. doi: 10.1002/cncr.30639. Epub 2017 May 2.
8
Socioeconomic and Racial/Ethnic Disparities in Cancer Mortality, Incidence, and Survival in the United States, 1950-2014: Over Six Decades of Changing Patterns and Widening Inequalities.1950 - 2014年美国癌症死亡率、发病率及生存率的社会经济和种族/民族差异:六十多年来不断变化的模式与日益扩大的不平等
J Environ Public Health. 2017;2017:2819372. doi: 10.1155/2017/2819372. Epub 2017 Mar 20.
9
Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.影响慢性粒细胞白血病治疗依从性的因素及改善方法:一项由患者主导的对63个国家2546名患者的调查结果
J Cancer Res Clin Oncol. 2017 Jul;143(7):1167-1176. doi: 10.1007/s00432-017-2372-z. Epub 2017 Mar 13.
10
The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.社会经济因素对慢性髓性白血病治疗选择和死亡率的影响。
Eur J Haematol. 2017 Apr;98(4):398-406. doi: 10.1111/ejh.12845. Epub 2017 Jan 16.